Arcus Biosciences and Beijing Biotech side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Arcus Biosciences | Beijing Biotech |
|---|---|---|
| Phase 1 | Arcus Biosciences: 1 of its 3 programs at phase 1
| Beijing Biotech: 1 of its 40 programs at phase 1
|
| Phase 2 | 00% | Beijing Biotech: 39 of its 40 programs at phase 2
and 34 more — sign in to see them all |
| Phase 3 | Arcus Biosciences: 2 of its 3 programs at phase 3
| 00% |
| Approved, new studies | 00% | 00% |
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arcus Biosciences2 readouts · 0 phase 3 | · | Arcus Biosciences, Dec ’26: 1 program whose next study reaches primary completion
| · | · | · | · | Arcus Biosciences, May ’27: 1 program whose next study reaches primary completion
| · | · | · | · | · |
| Beijing Biotech40 readouts · 0 phase 3 | · | · | · | Beijing Biotech, Feb ’27: 11 programs whose next study reaches primary completion
and 6 more — sign in to see them all | Beijing Biotech, Mar ’27: 21 programs whose next study reaches primary completion
and 16 more — sign in to see them all | Beijing Biotech, Apr ’27: 3 programs whose next study reaches primary completion
| · | Beijing Biotech, Jun ’27: 5 programs whose next study reaches primary completion
| · | · | · | · |
Changed in the last 90 days
Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Arcus Biosciences
New programs 0
None
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 0
None
Beijing Biotech
New programs 0
None
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 0
None
Where they overlap
Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.
| Condition | Arcus Biosciences | Beijing Biotech |
|---|---|---|
| Carcinoma, Non-Small-Cell Lungboth · compare here | Arcus Biosciences in Carcinoma, Non-Small-Cell Lung: 1 program
Their studies: Arcus Biosciences’ studies of Carcinoma, Non-Small-Cell Lung in search | Beijing Biotech in Carcinoma, Non-Small-Cell Lung: 2 programs
Their studies: Beijing Biotech’s studies of Carcinoma, Non-Small-Cell Lung in search |
| Clear-cell metastatic renal cell carcinomaboth · compare here | Arcus Biosciences in Clear-cell metastatic renal cell carcinoma: 1 program
Their studies: Arcus Biosciences’ studies of Clear-cell metastatic renal cell carcinoma in search | Beijing Biotech in Clear-cell metastatic renal cell carcinoma: 2 programs
Their studies: Beijing Biotech’s studies of Clear-cell metastatic renal cell carcinoma in search |
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
No gene two of them both target, among the programs whose target is known.
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.